Kymriah Side Effects: Cytokine Release Syndrome, Toxicity, Infections

Kymriah Side Effects: Cytokine Release Syndrome, Toxicity, Infections. Last 30 August 2017, the Food and Drug Administration (FDA) approved Kymriah cell therapy to treat children and young adults (up to 25 years of age) with B-cell acute lymphoblastic leukemia.

How is the treatment administered and what side effects should patients be aware of? Apparently, the treatment administration involves the collection of T-cells from the patient, modifying it, and injecting it back. More details from the FDA media release:

The patient’s T-cells are collected and sent to a manufacturing center where they are genetically modified to include a new gene that contains a specific protein (a chimeric antigen receptor or CAR) that directs the T-cells to target and kill leukemia cells that have a specific antigen (CD19) on the surface. Once the cells are modified, they are infused back into the patient to kill the cancer cells.

Continue reading

Flakka Side Effects: Death, Insanity, Delirium

Flakka Side Effects. There’s a new recreational drug out there that’s been hogging the headlines lately because it is more dangerous than “bath salts”. It’s called Flakka.

Here’s what Jim Hall, an epidemiologist at the Center for Applied Research on Substance Use and Health Disparities at Nova Southeastern University is saying about the drug’s effects on the human body (via CBS):

We’re starting to see a rash of cases of a syndrome referred to as excited delirium. This is where the body goes into hyperthermia, generally a temperature of 105 degrees. The individual becomes psychotic, they often rip off their clothes and run out into the street violently and have an adrenaline-like strength and police are called and it takes four or five officers to restrain them. Then once they are restrained, if they don’t receive immediate medical attention they can die.

Continue reading

Shingrix Side Effects: Pain, Redness, Headache

Shingrix Side Effects. Last month, the Food and Drug Administration approved Shingrix (by GlaxoSmithKline) for the prevention of shingles among adults aged 50 and over. This approval came after a clinical trial involving 38,000 people which demonstrated the efficacy of the vaccine. In this trial, participants who were given Shingrix demonstrated efficacy against shingles greater than 90%. Moreover, follow-ups over a period of four years has shown the sustained efficacy of the vaccine.

Shingrix was developed specifically to overcome the age-related decline in immunity to shingles (herpes zoster) which, currently, affects 1 in 3 people in the United States. Want more vaccine side effects?

Continue reading